ITIL-306 in Advanced Solid Tumors
Phase 1 Terminated
1 enrolled
Safety and Efficacy of Tisotumab Vedotin Monotherapy & in Combination With Other Cancer Agents in Subjects With Cervical Cancer
Phase 1/2 Terminated
214 enrolled
Prospective Randomised Phase II Trial Evaluating Adjuvant Pelvic Radiotherapy Using Either IMRT or 3-Dimensional Planning for Endometrial Cancer. ICORG 09-06
Phase 2 Terminated
92 enrolled
GEN1047 for Solid Tumors - First in Human (FIH) Trial
Phase 1/2 Terminated
179 enrolled
A Study of Apatinib Combined With Letrozole With or Without Fluzoparib in Estrogen Receptor-Positive, Platinum-Sensitive Recurrent Ovarian Cancer Previously Treated With First-Line PARP Inhibitor
Phase NA Terminated
5 enrolled
Dose Escalation and Dose Expansion Study of CPO-100 in Patients With Advanced Solid Tumors
Phase 1 Terminated
34 enrolled
RaPiDS- A Phase 2 Study of Anti-PD-1 Independently or in Combination With Anti-CTLA-4 in Second-Line Cervical Cancer
Phase 2 Terminated
211 enrolled
Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors
Phase 1 Terminated
115 enrolled 43 charts
A Phase II Study of Futibatinib and Pembrolizumab in Metastatic Microsatellite Stable Endometrial Carcinoma
Phase 2 Terminated
9 enrolled 10 charts
TILsOV
Phase NA Terminated
36 enrolled
ACCRAPAN
Phase 2 Terminated
21 enrolled
GEMCOL
Phase 2 Terminated
19 enrolled
ANOXICOL
Phase NA Terminated
9 enrolled
Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected
Phase 3 Terminated
358 enrolled
Anti-PD-1 Antibody Combined With Histone Deacetylase Inhibitor in Patients With Advanced Cervical Cancer
Phase 1/2 Terminated
5 enrolled
Intraperitoneal Paclitaxel-loaded TPM for Treatment of Peritoneal Carcinomatosis
Phase 1 Terminated
4 enrolled
PRO1107 in Patients With Advanced Solid Tumors
Phase 1/2 Terminated
33 enrolled
First-in-Human Study of ATX-559, an Oral Inhibitor of DHX9, in Patients With Advanced or Metastatic Solid Tumors, and Molecularly Defined Cancers
Phase 1 Terminated
17 enrolled
A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the Body of People With Cancer When Taken Alone or With Other Anti-cancer Medicines.
Phase 1 Terminated
10 enrolled
A Study of ABI-2280 Vaginal Insert (Previously Referred to as ABI-2280 Vaginal Tablet) in Participants With Cervical Intraepithelial Neoplasia
Phase 1/2 Terminated
44 enrolled
FAB
Phase 2 Terminated
27 enrolled
Combination of SON-1010 (IL12-FHAB) and Atezolizumab in Patients With Platinum-resistant Ovarian Cancer
Phase 1/2 Terminated
40 enrolled
A Study of PHN-010 in Patients With Advanced Solid Tumors
Phase 1 Terminated
26 enrolled
HPV16 E6 TCR T Cells for Cervical Carcinoma
Phase 1/2 Terminated
5 enrolled
A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers
Phase 1/2 Terminated
73 enrolled
Phase 2 Study of PI3K Inhibitor Copanlisib in Combination With Fulvestrant in Selected ER+ and/or PR+ Cancers With PI3K (PIK3CA, PIK3R1) and/or PTEN Alterations
Phase 2 Terminated
7 enrolled 10 charts
A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors
Phase 1 Terminated
250 enrolled
Efficacy and Safety of TQB2450 Injection Combined With Chemotherapy ± Anlotinib Hydrochloride Capsules for Advanced Endometrial Cancer or Sarcoma of Uterus.
Phase 2 Terminated
71 enrolled
Promitil Treatment of Patients With Solid Tumors Associated With Deleterious Mutations Who Have Progressed After Therapy
Phase 2 Terminated
19 enrolled
Intraperitoneal Infusion of Autologous Monocytes With Sylatron (Peginterferon Alfa-2b) and Actimmune (Interferon Gamma-1b) in Women With Recurrent or Refractory Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer
Phase 1 Terminated
18 enrolled 19 charts
Conservative Surgery in Treating Patients With Low-Risk Stage IA2 or IB1 Cervical Cancer
Phase NA Terminated
137 enrolled 15 charts
A Phase 1 Study of [225Ac]-FPI-1434 Injection
Phase 1 Terminated
78 enrolled
BASICS
Phase NA Terminated
3 enrolled
ENDOCOL
Phase NA Terminated
3 enrolled
Letrozole as Maintenance Therapy for Post-surgical Endometrial Cancer Patients With NSMP
Phase 2/3 Terminated
12 enrolled
MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer
Phase 2 Terminated
17 enrolled 14 charts
A Phase I Clinical Study of Recombinant Humanized Anti-BTLA Monoclonal Antibody (JS004) Injection Combined With Toripalimab Injection in Patients With Advanced Solid Tumors
Phase 1 Terminated
31 enrolled
(VELA) Study of BLU-222 in Advanced Solid Tumors
Phase 1 Terminated
50 enrolled
A Study Comparing Niraparib Versus Platinum-Taxane Doublet Chemotherapy as Neoadjuvant Treatment in Participants With Homologous Recombination-Deficient Stage III/IV Ovarian Cancer (COHORT-C)
Phase 2 Terminated
36 enrolled 11 charts
A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid Tumors
Phase 2 Terminated
166 enrolled 43 charts
Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced Malignancies
Phase 1 Terminated
17 enrolled
A Study of PF-06873600 in People With Cancer
Phase 1/2 Terminated
155 enrolled 44 charts
Phase 1/2a Study of SQ3370 in Patients With Advanced Solid Tumors
Phase 1/2 Terminated
53 enrolled 23 charts
Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors
Phase 1/2 Terminated
8 enrolled 12 charts
NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors
Phase 1 Terminated
82 enrolled
ARTIST
Phase 2 Terminated
36 enrolled
PAVO
Phase 2 Terminated
22 enrolled 17 charts
Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies
Phase 1/2 Terminated
137 enrolled 31 charts
An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies
Phase 1 Terminated
25 enrolled
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors
Phase 1 Terminated
105 enrolled